(Q35612263)

9 August 2017

1 reference

title

Cortisol and the renal handling of electrolytes: role in glucocorticoid-induced hypertension and bone disease (English)

1 reference

9 August 2017

0 references

Paolo Ferrari

1

0 references

publication date

1 December 2003

1 reference

Best Practice and Research: Clinical Endocrinology and Metabolism

9 August 2017

published in

1 reference

9 August 2017

volume

17

1 reference

9 August 2017

issue

4

1 reference

9 August 2017

page(s)

575-589

1 reference

Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Clinical review 83: Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Role of the 11beta-hydroxysteroid dehydrogenase type 2 in blood pressure regulation

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

The 11 beta-hydroxysteroid dehydrogenase type II enzyme: biochemical consequences of the congenital R337C mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Mechanisms of glucocorticoid action in bone

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Calcium metabolism and parathyroid function in primary aldosteronism

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Modulation of renal calcium handling by 11 beta-hydroxysteroid dehydrogenase type 2.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Forms of mineralocorticoid hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Mineralocorticoid hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Juvenile hypertension, the role of genetically altered steroid metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Genetics of the mineralocorticoid system in primary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Cloning of the 11βHSD type II enzyme from human kidney

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Cloning and tissue distribution of the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Immunohistochemical localization of the 11 beta-hydroxysteroid dehydrogenase type II enzyme in human kidney and placenta

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Evidence for an unidentified steroid in a child with apparent mineralocorticoid hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

A Syndrome of Apparent Mineralocorticoid Excess Associated with Defects in the Peripheral Metabolism of Cortisol*

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

The R337C mutation generates a high Km 11 beta-hydroxysteroid dehydrogenase type II enzyme in a family with apparent mineralocorticoid excess

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Several homozygous mutations in the gene for 11 beta-hydroxysteroid dehydrogenase type 2 in patients with apparent mineralocorticoid excess

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Point mutations abolish 11 beta-hydroxysteroid dehydrogenase type II activity in three families with the congenital syndrome of apparent mineralocorticoid excess.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

A genetic defect resulting in mild low-renin hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

In vivo 11beta-HSD-2 activity: variability, salt-sensitivity, and effect of licorice

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Urinary free corticoids: an evaluation of their usefulness in the diagnosis of Cushing's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Cortisol inactivation overload: a mechanism of mineralocorticoid hypertension in the ectopic adrenocorticotropin syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Urinary free cortisone and the assessment of 11 beta-hydroxysteroid dehydrogenase activity in man

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Evidence That High Dose Cortisol-Induced Na+Retention in Man Is not Mediated by the Mineralocorticoid Receptor*

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Mode of spirolactone action: competitive inhibition of aldosterone binding to kidney mineralocorticoid receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Mineralocorticoid receptors in the central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Cure of apparent mineralocorticoid excess by kidney transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Plasma Renin Activity and Urinary Aldosterone in Cushing's Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Response of Several Adrenal Steroids to ACTH Stimulation in Essential Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Associations between aldosterone synthase gene polymorphism and the adrenocortical function in males

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Cortisol and hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Effects of oral L-arginine on plasma nitrate and blood pressure in cortisol-treated humans

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Oral corticosteroids and fracture risk: relationship to daily and cumulative doses

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Cytochemical demonstration of the glucocorticoid receptor in skeletal cells of the rat

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Regulation of bone sialoprotein and osteopontin mRNA expression by dexamethasone and 1,25-dihydroxyvitamin D3 in rat bone organ cultures

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Biochemical, histomorphometric and densitometric changes in patients with multiple myeloma: effects of glucocorticoid therapy and disease activity.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Differential effect of glucocorticoids on calcium absorption and bone mass

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Glucocorticoid-Induced Osteoporosis: Pathogenesis and Management

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Glucocorticoid osteoporosis--mechanisms and management

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

High-dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Calcium intake, calcium excretion and blood pressure in adolescents in the upper decile of the distribution: the Torrejon study.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Rabbit distal convoluted tubule coexpresses NaCl cotransporter and 11 beta-hydroxysteroid dehydrogenase II mRNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Dual Sites of Inhibition by Metyrapone of Human Adrenal Steroidogenesis: Correlation ofin Vivoand andin VitroStudies

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Ketoconazole-induced increase in estradiol-testosterone ratio. Probable explanation for gynecomastia

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Ketoconazole blocks cortisol secretion in man by inhibition of adrenal 11 beta-hydroxylase

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Ketoconazole treatment in Cushing's syndrome: experience in 34 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Use of ketoconazole in the treatment of Cushing's disease and ectopic ACTH syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Aminoglutethimide in the treatment of Cushing's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Prolonged bleeding time due to mitotane therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

5 Cushing's syndrome and exogenous glucocorticoid hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Response of hypertension to conventional antihypertensive treatment and/or steroidogenesis inhibitors in Cushing's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Therapeutic value of calcium antagonists in autonomous hyperaldosteronism

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Are calcium antagonists helpful in the management of primary aldosteronism?

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Corticosteroids and bone mass in asthma: comparisons with rheumatoid arthritis and polymyalgia rheumatica.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Antiresorptive therapy in asthmatic patients receiving high-dose inhaled steroids: a prospective study for 18 months.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Effects of hydrochlorothiazide and dietary sodium restriction on calcium metabolism in corticosteroid treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults. A randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Renal calcium metabolism and diuretics

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Sodium transport and bone mineral density in hypercalciuria with thiazide treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Thiazide diuretic agents and the incidence of hip fracture

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Effects of thiazide diuretic therapy on bone mass, fractures, and falls. The Study of Osteoporotic Fractures Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Markers of bone metabolism in postmenopausal women with rheumatoid arthritis. Effects of corticosteroids and hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900053-8

7 January 2021

10.1016/S1521-690X(03)00053-8

Identifiers

DOI

1 reference

9 August 2017

1 reference